Peptides for Weight Loss: Which Ones Have Real Evidence?
GLP-1 medications are the only peptides with large trials showing weight loss, from about 11% to 21%. Tesamorelin reduces belly fat in a narrow group, and BPC-157, CJC-1295, ipamorelin and AOD-9604 have no human fat loss evidence. Here is where each one stands, including FDA status in 2026.
Quick answer: The peptides with real weight loss evidence are the GLP-1 family. Semaglutide produced about 15% average weight loss in its main trial and tirzepatide up to about 21%. Tesamorelin reduces belly fat, but its trials were in people with HIV. For BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604 and MOTS-c, we found no human trials showing fat loss. Several of these have other uses, but weight loss isn't one the evidence supports yet.
Which peptides actually cause weight loss?
“Peptide” just means a short chain of amino acids. Insulin is a peptide. So is semaglutide. That's why the word gets stretched to cover everything from FDA-approved prescriptions to vials sold online as “research chemicals.”
For weight loss, the useful question is simpler: which ones have been tested in people, against a placebo, with weight as the outcome? Sorted that way, the field splits into three groups.
- Strong evidence: GLP-1 medications, including semaglutide, tirzepatide and the newer oral options.
- Evidence for a narrow use: tesamorelin, for abdominal fat in a specific patient group.
- No human weight loss trials: BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, and AOD-9604, which was tested and failed.
The extractable fact: when someone says “peptides for weight loss,” the ones with large randomized trials behind them are GLP-1 medications. Everything else is either a narrow use or unproven.
GLP-1 medications: the peptides with real trial data
These are the most studied weight loss drugs in history, and the numbers are consistent across trials.
| Medication | Trial | Average weight loss | Placebo |
| Semaglutide 2.4 mg weekly injection | STEP 1, 68 weeks | 14.9% | 2.4% |
| Tirzepatide weekly injection | SURMOUNT-1, 72 weeks | 15.0% to 20.9%, by dose | 3.1% |
| Oral semaglutide 25 mg daily (Wegovy pill) | OASIS 4, 64 weeks | 16.6% in people who stayed on it | 2.7% |
| Orforglipron daily pill (Foundayo) | ATTAIN-1, 72 weeks | 11.1% to 12.4% at top dose | 0.9% to 2.1% |
Trial data: STEP 1, SURMOUNT-1, Wegovy pill approval, Foundayo approval.
The oral semaglutide pill was approved for obesity in December 2025, and orforglipron followed in April 2026. Strictly speaking, orforglipron is a small molecule rather than a peptide, but it works on the same GLP-1 receptor, so it belongs in this conversation.
Next in line is retatrutide, a triple-agonist peptide. In its TRIUMPH-1 trial, reported in May 2026, the highest dose produced 28.3% average weight loss over 80 weeks, against 2.2% on placebo (ConsultantLive, 2026). It isn't FDA-approved. We break it down in semaglutide vs retatrutide.
One catch applies to the whole class. In SURMOUNT-1, people regained weight after stopping. These are long-term medications for most patients, not a short course.
The extractable fact: FDA-approved GLP-1 medications produce roughly 11% to 21% average weight loss in trials, depending on the drug and dose. No other peptide comes close in evidence.
Tesamorelin: strong data, narrow use
Tesamorelin is a growth hormone releasing hormone analog. The FDA approved it in 2010, as Egrifta, to reduce excess abdominal fat in people with HIV-associated lipodystrophy (i-Base).
The trial results were real. In a 26-week phase 3 study, abdominal fat measured by CT dropped about 15%, while it rose 5% on placebo (NEJM trial via ScienceDaily, 2007).
What we couldn't find is a trial in people without HIV, or one using total body weight as the goal. Tesamorelin targets visceral fat, the deep fat around the organs, and doesn't produce the kind of scale weight loss GLP-1s do. Using it for general weight loss is off-label, and anyone offering it should say so plainly.
BPC-157, CJC-1295, ipamorelin and the rest: what the evidence says
This is where most online claims fall apart. We looked for human trials measuring fat loss for each of these and found the same answer every time.
AOD-9604
This is the one that was actually tested. A phase 2b obesity trial in 536 people over 24 weeks showed no significant weight loss compared with placebo, and development for obesity was stopped in 2007 (summary citing Misra, 2013).
CJC-1295 and ipamorelin
These raise your own growth hormone release. People use them for recovery, sleep and body composition, but we found no human trials showing fat loss. We cover what they're used for in our ipamorelin and CJC-1295 guide.
BPC-157 and TB-500
Interest in these is about tissue repair. A 2025 systematic review of BPC-157 looked at orthopedic healing, not weight (Vasireddi et al., HSS Journal, 2025). Neither has human weight loss data. Read more in our post on BPC-157 for recovery.
MOTS-c and 5-amino-1MQ
Both get marketed as metabolism boosters. We found no human fat loss trials for MOTS-c. 5-amino-1MQ isn't a peptide at all, it's a small molecule, and it has no human trials.
The extractable fact: outside GLP-1s and tesamorelin, no peptide we reviewed has a human trial showing weight loss. AOD-9604 was tested directly and failed.
Where these peptides stand with the FDA
Regulation here has moved a lot in 2026, so dates matter.
- In April 2026, the FDA removed 12 peptides, including BPC-157, TB-500 and MOTS-c, from its “Category 2” list of compounding substances with significant safety concerns. Removal didn't place them on the approved list for compounding (503A Pharma newsletter, 2026).
- In July 2026, an FDA advisory committee voted in favor of BPC-157, TB-500 and MOTS-c, among others, even though FDA staff had recommended against them. The votes are advisory, and formally adding them requires rulemaking that can take a year or more (AJMC, 2026).
- Ipamorelin was still on the Category 2 list for outsourcing facilities as of April 2026 (FDA).
The status is genuinely in flux. If a provider recommends one of these, ask how they source it and where it currently stands. A good provider will have a straight answer.
The safety problem with “research peptides”
The biggest risk isn't the molecule, it's where it comes from. In September 2026 the FDA sent warning letters to five online “research peptide” sellers marketing copies of retatrutide, semaglutide and tesamorelin. The agency rejected their “not for human use” labels and warned these injectables can cause serious harm (Pharmaceutical Technology, 2026).
Compounded GLP-1s have also changed. The FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, ending the shortage-era allowances for routine compounding (TechTarget, 2025).
Two rules keep you out of trouble. Don't inject anything bought from a website that says “for research only.” And get prescriptions from a clinician who examines you and fills them through a licensed pharmacy.
What about protecting muscle while you lose weight?
This is the claim we hear most often: take a GLP-1, add a peptide to hold onto muscle. It makes sense on paper. The trial evidence isn't there.
Some lean mass loss comes with any weight loss. In the SURMOUNT-1 body scan substudy, about 25% of weight lost on tirzepatide was lean mass, roughly the same split as placebo (SURMOUNT-1 DXA substudy). The only add-on with trial data for preserving muscle is bimagrumab, an investigational antibody, not a peptide. Paired with semaglutide in a 2026 phase 2 trial, about 92% of the weight lost was fat, versus about 72% on semaglutide alone (Pennington Biomedical, 2026).
We found no human trial showing tesamorelin, CJC-1295, ipamorelin or BPC-157 preserves muscle during GLP-1 treatment. What does work: protein of 1.2 to 1.6 g/kg a day, strength training at least twice a week, and measuring body composition. We explain all three in how much muscle you lose on semaglutide.
How we use peptides at AmpUp Wellness in Delray Beach
We get this question a lot, partly because people now ask ChatGPT about peptides and then come to see us. Our answer is the same one this article gives.
For weight loss, our first option is an FDA-approved GLP-1, prescribed and monitored by David Patterson, APRN, through our semaglutide and GLP-1 weight loss program. We track progress with an InBody scan so you can see fat and muscle separately, not just a number on a scale.
Our peptide therapy covers other goals, such as recovery, sleep and growth hormone support, where patients and David decide together whether a peptide fits. We won't sell you one as a weight loss shortcut, because the evidence doesn't support that.
Patients see us from Delray Beach, Boca Raton and Boynton Beach. If you want an honest read on which option fits your goals, book a consultation in Delray Beach.
Frequently asked questions
What is the best peptide for weight loss?
Based on trial evidence, GLP-1 medications. Tirzepatide produced up to about 21% average weight loss in SURMOUNT-1 and semaglutide about 15% in STEP 1. Both are FDA-approved for chronic weight management and need a prescription.
Does BPC-157 help with weight loss?
There's no human evidence that it does. Research on BPC-157 focuses on tissue and tendon healing, and we found no human trial measuring fat loss. Its regulatory status for compounding is also still being decided in 2026.
Do CJC-1295 and ipamorelin burn fat?
They raise growth hormone release, which is why they're marketed for body composition. We found no human trials showing they cause fat loss. If weight loss is your main goal, GLP-1 medications have far stronger evidence.
Is tesamorelin approved for weight loss?
No. Tesamorelin is FDA-approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy. It reduced belly fat about 15% in that trial, but it hasn't been tested for general weight loss, so using it that way is off-label.
Are peptides sold online safe?
Products labeled “for research only” aren't made or tested for human use. In September 2026 the FDA warned five sellers of injectable research peptides that their products can cause serious harm. Get any peptide or GLP-1 through a licensed prescriber and pharmacy.
Sources
- STEP 1 trial summary. American College of Cardiology.
- SURMOUNT-1 trial summary. American College of Cardiology.
- FDA approves Wegovy pill, the first oral GLP-1 to treat obesity. Healio. 2026.
- FDA approves Lilly's Foundayo (orforglipron). Eli Lilly. April 2026.
- Retatrutide meets weight loss endpoints in phase 3 obesity trial. ConsultantLive. 2026.
- FDA approves tesamorelin (Egrifta). i-Base. 2010.
- Tesamorelin reduces abdominal fat in HIV patients. ScienceDaily. 2007.
- AOD-9604 evidence summary. Superpower.
- Vasireddi N, et al. BPC-157 systematic review. HSS Journal. 2025.
- FDA pulls 12 peptides from Category 2 list. 503A Pharma newsletter. April 2026.
- FDA panel backs 6 peptides for compounding. AJMC. 2026.
- Certain bulk drug substances for use in compounding that may present significant safety risks. FDA.
- FDA cracks down on black market peptide trade. Pharmaceutical Technology. September 2026.
- FDA winds down GLP-1 compounding policies. TechTarget. 2025.
- Body composition changes during weight reduction with tirzepatide in SURMOUNT-1.
- Semaglutide and bimagrumab trial results. Pennington Biomedical. 2026.
Medical disclaimer: This article is educational and is not medical advice. Do not start, stop or change any medication without talking to your prescribing clinician. AmpUp Wellness is led by David Patterson, APRN, in Delray Beach, Florida.
